David Schenkein, M.D.

Dr. Schenkein is a hematologist, medical oncologist, and entrepreneur. He serves as an adjunct clinical professor in hematology at Tufts Medical Center and a general partner at GV (formerly Google Ventures), where he co-leads the life science investment team.

He previously served as CEO and chairman of Agios, and Senior Vice President of Clinical Hematology/Oncology at Genentech, Inc. Dr. Schenkein was responsible for numerous successful oncology drug approvals while at Genentech, and concurrently served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the Senior Vice President of Clinical Research at Millennium Pharmaceuticals, Inc. (now a wholly owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of VELCADE®, a cancer therapy for treating multiple myeloma and non-Hodgkins lymphoma. He currently serves on the board of directors of several biopharmaceutical companies.

Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.